Yonggui Hong

机构：Anyang Tumor Hospital

发表论文 26 篇 · 总被引 171 次 · h-index 6

代表论文

• Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial (2022 · ˜The œLancet. Gastroenterology & hepatology · 被引 88)
• Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study (2024 · European Journal of Cancer · 被引 21)
• A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma (2022 · BMC Medicine · 被引 13)
• Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial (2025 · Molecular Cancer · 被引 10)
• First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study (2024 · Signal Transduction and Targeted Therapy · 被引 7)
• Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study (2024 · The Oncologist · 被引 7)